FDA clears investigational new drug application for geographic atrophy treatment
Click Here to Manage Email Alerts
Key takeaways:
- The FDA cleared an investigational new drug application for AVD-104 for geographic atrophy treatment.
- The phase 2 SIGLEC trial is expected to begin later this year.
The FDA cleared an investigational new drug application for AVD-104 for the treatment of geographic atrophy secondary to age-related macular degeneration, Aviceda Therapeutics announced in a press release.
The phase 2 SIGLEC trial of the intravitreal nanoparticle molecule is expected to begin in the second quarter.
Image: Adobe Stock
AVD-104 is designed to inhibit the activity of retinal macrophages, repolarize activated macrophages to their resolution state and inhibit complement cascade amplification, the release said.
“The FDA’s acceptance of our IND application to initiate the clinical evaluation of AVD-104 brings us one step closer to introducing a potentially paradigm-shifting treatment for people living with geographic atrophy and macular degeneration,” Mohamed Genead, MD, Aviceda’s co-founder, president and CEO, said in the release. “The AVD-104 IND clearance marks an important milestone for Aviceda as we continue our track record of execution as the leader in the glycome field.”
Read more about
Click Here to Manage Email Alerts